Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

[Research Progress of Acquired Resistance Mediated by MET Amplification  in Advanced Non-small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Aug 2022

Pan Sisi, Wang Na, Song Xia

Abstract excerpt

Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a...

Topics

Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-met

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 36002199
DOI: 10.3779/j.issn.1009-3419.2022.102.23
PMCID: PMC9411950

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].PMID 36002199Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

The coexistence of MET over-expression and an <i>EGFR</i> T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerSemantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cellsSemantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.